Trial site
Lehigh Center for Clinical Research
Allentown, Pennsylvania 18104, United StatesNot linked to an institution yet
- 11running trials
- 13closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 28 trials
- Phase 41 trial
- Status
- Completed11 trials
- Active, not recruiting6 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Xenon Pharmaceuticals Inc.4 trials
- Janssen Research & Development, LLC3 trials
- TriGemX Bio, Inc.3 trials
- Biohaven Pharmaceuticals, Inc.2 trials
- Biohaven Therapeutics Ltd.2 trials
- and 8 more
Running trials
Not yet recruiting
A Study of Brenipatide in Participants With Major Depressive Disorder
NCT07928245· Phase 2· Eli Lilly and Company· Source
Contact: Paul Gross (principal investigator)
Recruiting
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654· Phase 3· TriGemX Bio, Inc.· Source
Contact: Annemarie Vance
Recruiting
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924· Phase 3· TriGemX Bio, Inc.· Source
Contact: Annemarie Vance
Recruiting
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT07115329· Phase 2· Syndeio Biosciences, Inc· Source
Contact: Karen Raudibaugh
Active, not recruiting
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860· Phase 3· Xenon Pharmaceuticals Inc.· Source
Active, not recruiting
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516· Phase 3· Xenon Pharmaceuticals Inc.· Source
Active, not recruiting
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110· Phase 3· Xenon Pharmaceuticals Inc.· Source
Recruiting
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489· Phase 2· Syndeio Biosciences, Inc· Source
Contact: Karen Raudibaugh
Active, not recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379· Phase 3· Xenon Pharmaceuticals Inc.· Source
Active, not recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479· Phase 2· AbbVie· Source
Active, not recruiting
Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis
NCT06121882· Phase 3· Lipogems International spa· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Recruiting
A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)
NCT07219771· Phase 3· Doron Therapeutics Inc.· Source
Contact: Mary Kathryn Kottke
Completed
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075· Phase 2· TriGemX Bio, Inc.· Source
Completed
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source
Completed
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source
Completed
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT06000410· Phase 3· Organogenesis· Source
Completed
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030· Janssen Research & Development, LLC· Source
Completed
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
NCT04770220· Phase 3· Alzheon Inc.· Source
Terminated
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT04708834· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
NCT04693351· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT04636229· Phase 3· Organogenesis· Source
Completed
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
NCT04521478· Phase 2· Boehringer Ingelheim· Source
Completed
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
NCT04599855· Phase 4· Janssen Research & Development, LLC· Source
Completed
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529· Phase 3· Janssen Research & Development, LLC· Source
Report an error